Studies

Tirzepatide Trial Demonstrates Substantial Weight Loss.

JAMA|2022|Slomski A|3 citations

PMID: 35881126

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.

The lancet. Diabetes & endocrinology|2022|Kadowaki T et al.|99 citations

BACKGROUND: Due to potential ethnic differences in the pathophysiology of type 2 diabetes, new therapeutics need to be evaluated in Japanese patients. We aimed to assess the safety and glycaemic efficacy of tirzepatide as an add-on treatment in Japan…

Randomized Controlled Trial

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.

The lancet. Diabetes & endocrinology|2022|Inagaki N et al.|171 citations

BACKGROUND: As the disease progresses, many patients with type 2 diabetes have difficulty in reaching treatment goals. We aimed to assess the efficacy and safety of tirzepatide, a novel GIP and GLP-1 receptor agonist, compared with dulaglutide in Jap…

Randomized Controlled TrialTirzepatide

PMID: 35914543

Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue.

Molecular metabolism|2022|Samms R et al.|72 citations

OBJECTIVES: Tirzepatide, a dual GIP and GLP-1 receptor agonist, delivered superior glycemic control and weight loss compared to selective GLP-1 receptor (GLP-1R) agonism in patients with type 2 diabetes (T2D). These results have fueled mechanistic st…

Animal StudyTirzepatide

PMID: 35921984

Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control.

Journal of the American Heart Association|2022|Chiu N, Aggarwal R, Bhatt D|4 citations

Tirzepatide

PMID: 35929468

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.

TouchREVIEWS in endocrinology|2022|Kaneko S|18 citations

Gastrointestinal hormones are currently used to treat type 2 diabetes mellitus (T2D). Incretin preparations with gastric inhibitory polypeptide (GIP) activity or glucagon-like peptide-1 (GLP-1) provide new means for controlling blood glucose levels,…

ReviewTirzepatide

PMID: 35949358

Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide.

The American journal of cardiology|2022|Patoulias D et al.|19 citations

Meta-AnalysisTirzepatide

PMID: 35977865

An Introduction to Tirzepatide.

Clinical diabetes : a publication of the American Diabetes Association|2022|Bertsch T|4 citations

Tirzepatide

PMID: 35983423

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.

Cardiovascular diabetology|2022|McGuire D et al.|7 citations

Cardiovascular (CV) outcome trials (CVOTs) of type 2 diabetes mellitus (T2DM) therapies have mostly used randomized comparison with placebo to demonstrate non-inferiority to establish that the investigational drug does not increase CV risk. Recently,…

ReviewTirzepatide

PMID: 36002856

Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Medical science monitor : international medical journal of experimental and clinical research|2022|Ordóñez-Vázquez A et al.|12 citations

Worldwide, metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic liver disease. MAFLD is associated with insulin resistance, type 2 diabetes mellitus (T2DM), obesity, hypertension, and dyslipidemia. Early diagnosis a…

Tirzepatide

PMID: 36093924

Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis.

Frontiers in cardiovascular medicine|2022|Yu Y et al.|14 citations

OBJECTIVE: The purpose of this study is to evaluate the optimal dose of tirzepatide (TZP) for the treatment of type 2 diabetes mellitus (T2DM) by meta-analysis and trial sequential analysis (TSA). METHODS: Clinical trials of TZP for T2DM were obtaine…

ReviewTirzepatide

PMID: 36119737

Tirzepatide and kidney function: an intriguing and promising observation.

The lancet. Diabetes & endocrinology|2022|Solini A|3 citations

Tirzepatide

PMID: 36152638

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.

The lancet. Diabetes & endocrinology|2022|Heerspink H et al.|209 citations

BACKGROUND: In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide reduced HbAconcentrations, bodyweight, and blood pressure more than titrated daily insulin glargine in people with type 2 diabetes inadequately controlled on oral…

Randomized Controlled TrialTirzepatide

PMID: 36152639

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.

Frontiers in endocrinology|2022|Lisco G et al.|12 citations

Tirzepatide, a dual agonist of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide 1 (GLP-1) receptors, improved glucose control and reduced body weight in different therapeutic approaches. Herein, we overviewed the role of G…

ReviewMeta-AnalysisTirzepatide

PMID: 36157450

In adults with obesity without diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.

Annals of internal medicine|2022|Davidson M|1 citation

Jastreboff AM, Aronne LJ, Ahmad NN, et al.N Engl J Med. 2022;387:205-16. 35658024.

Tirzepatide

PMID: 36191308

Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?

Therapeutics and clinical risk management|2022|Razzaki T, Weiner A, Shukla A|9 citations

Tirzepatide is a novel "twincretin" with glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist activity, which was recently approved by the Food and Drug Administration for the treatment of type 2 diabetes mellitus…

ReviewTirzepatide

PMID: 36199834

Tirzepatide Once Weekly for the Treatment of Obesity.

The New England journal of medicine|2022|Dekker T|7 citations

Tirzepatide

PMID: 36239652

Tirzepatide Once Weekly for the Treatment of Obesity.

The New England journal of medicine|2022|Hagerich K, Durkee M, Goldstein M|18 citations

Tirzepatide

PMID: 36239653

Tirzepatide Once Weekly for the Treatment of Obesity.

The New England journal of medicine|2022|Venniyoor A|9 citations

Tirzepatide

PMID: 36239654

Tirzepatide Trial Demonstrates Substantial Weight Loss.

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.

Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue.

Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control.

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.

Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide.

An Introduction to Tirzepatide.

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.

Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Toward a new model for the management of type 2 diabetes: The mountain is there and there is no other option than to climb it.

Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis.

Tirzepatide and kidney function: an intriguing and promising observation.

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.

In adults with obesity without diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.

Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?

Tirzepatide Once Weekly for the Treatment of Obesity.

Tirzepatide Once Weekly for the Treatment of Obesity.

Tirzepatide Once Weekly for the Treatment of Obesity.